Growth hormone receptor antagonists: Potential indications;Groeihormoonreceptorantagonisten: Potentiële indicaties

Nederlands Tijdschrift voor Geneeskunde

Volumn 145, Issue 2, 2001, Pages 69-73

  Muller, A F ^a   Janssen, J A M J L ^a   De Herder, W W ^a   Van der Lely, A J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; PEGVISOMANT; UNCLASSIFIED DRUG;

ACROMEGALY; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; COLON CANCER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG RECEPTOR BINDING; HUMAN; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ACROMEGALY; ANIMALS; BREAST NEOPLASMS; CLINICAL TRIALS; COLONIC NEOPLASMS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; FEMALE; HUMAN GROWTH HORMONE; HUMANS; RECEPTORS, SOMATOTROPIN;

EID: 0035852507     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
2. Growth factors and diabetic nephrology: An overview
3. Growth factors and diabetic complication
4. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth
5. Diabetes, diabetic angiopathy, and growth hormone
6. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH
7. Mechanism of action of hormones that act at the cell surface
8. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule
9. Human growth hormone and extracellular domain of its receptor: Crystal structure of the complex
10. Crystals of the complex between human growth hormone and the extracellular domain of its receptor
11. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice
12. Amino acid residues in the third alpha-helix of growth hormone involved in growth promoting activity
13. Long-acting growth hormones produced by conjugation with polyethylene glycol
14. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human
15. Insulin-like growth factors and their receptors in growth
16. Pituitary surgery
17. Medical therapy for acromegaly
18. Octreotide
19. Safety and efficacy of long-term octreotidc therapy of acromegaly: Results of a multicenter trial in 103 patients - A clinical research center study
20. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure
21. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly
22. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly
23. The role of radiotherapy in acromegaly
24. Diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone in normals and juvenile diabetics
25. Abnormal growth hormone response to ingestion of glucose in juvenile diabetics
26. Glomerular hyperfiltration in insulin-dependent diabetes mellitus is correlated with enhanced growth hormone secretion
27. Growth hormone, the insulin-like growth factor system, and the kidney
28. Insulin-like growth factors. Studies in diabetics with and without retinopathy
29. The Houssay phenomenon in man: Recovery from retinopathy in a case of diabetes with Simmond's disease
30. Diabetes and anterior pituitary insufficiency. Final course and postmortem study of a diabetic patient with Sheehan's syndrome
31. Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy
32. Essential role of growth hormone in ischemia-induced retinal neovascularization
33. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice
34. Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice
35. A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin
36. Insulin-like growth factor-I and binding protein-3 and risk of cancer
37. Insulin-like growth factors and cancer
38. Autocrine stimulation of human mammary carcinoma cell proliferation by human growth hormone
39. High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice
40. IGF and insulin action in the mammary gland: Lessons from transgenic and knockout models
41. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia
42. Insulin-like growth factor I and prostate cancer risk: A population-based, case-control study
43. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis
44. Acromegaly, colonic polyps and carcinoma
45. Mortality and cancer incidence in acromegaly: A retrospective cohort study
46. The prevalence and characteristics of colorectal neoplasia in acromegaly
47. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
48. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3
49. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer